ELI-012 / Elicio Therap - LARVOL DELTA

Elicio Therapeutics Presents Preclinical Data on its Amphiphile-CpG Adjuvant at the STING & TLR-Targeting Therapies Summit 2022 Digital Event (GlobeNewswire) - "Elicio Therapeutics...announced the presentation of preclinical data demonstrating that its lymph node-targeted CpG TLR9 agonist, Amphiphile-CpG (AMP-CpG), induces potent immune and anti-tumor responses, at the STING & TLR-Targeting Therapies Summit 2022 Digital Event, being held virtually from March 22-24, 2022....AMP-CpG efficiently targets the lymph nodes to promote potent and comprehensive innate immune activation resulting in enhanced T and B cell responses with improved functionality and persistence."

Preclinical • Oncology • Solid Tumor

Elicio Therapeutics Presents Preclinical Data on AMP TCR-T and CAR-T Combination Therapies at the 2021 Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) - "Data showed Amphiphile (AMP) boosting significantly enhanced TCR-T cell anti-tumor efficacy and led to durable responses against solid tumors in an established, syngeneic tumor model. AMP boosting of CD19-specific CAR-T cells led to enhanced CAR-T activation and effector function suggesting the platform can potentially be utilized to improve clinical CD19 CAR-T cell therapies by boosting multiple axes of overall CAR-T fitness."

Preclinical • Oncology

Elicio Therapeutics Presents Preclinical Data on AMP TCR-T Combination Therapy in Solid Tumors at the CAR-TCR Annual Summit 2021 (GlobeNewswire) - “Data showed AMP combination with TCR-T cell therapy promotes durable responses against aggressive solid tumors in a mouse model where TCR-T cells alone have no effect. AMP combination with TCR-T cell therapy induces marked T cell expansion, solid tumor infiltration, and optimal phenotype/function correlated to durable responses. Improved durable responses in mice were associated with coordinated upregulation of inflammatory genes in lymphatics and tumor microenvironment which correlated to antigen spreading and enhanced endogenous T cell responses against diverse tumor antigens. Elicio Therapeutics…announced that it presented preclinical data on its Amphiphile (AMP) platform in combination with TCR-T therapy in solid tumors at the 6th Annual CAR-TCR summit, that was held virtually from August 30 – September 2, 2021.”

Preclinical • Oncology • Solid Tumor